Nephros, Inc.
Nephros, Inc. (NEPH) Stock Competitors & Peer Comparison
See (NEPH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NEPH | $4.19 | +0.24% | 44.4M | 34.92 | $0.12 | N/A |
| ISRG | $468.44 | -1.62% | 167.9B | 65.15 | $7.19 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.09% |
| BDX | $194.65 | -2.51% | 55.8B | 35.58 | $5.47 | +2.09% |
| RMD | $285.80 | -2.70% | 41.8B | 30.01 | $9.52 | +0.76% |
| ALC | $80.76 | -1.54% | 40B | 37.40 | $2.16 | +0.41% |
| WST | $247.21 | -0.26% | 17.8B | 36.94 | $6.69 | +0.34% |
| HOLX | $67.13 | -1.66% | 14.9B | 27.85 | $2.41 | N/A |
| COO | $73.48 | -2.31% | 14.7B | 35.50 | $2.07 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.09% |
Stock Comparison
NEPH vs ISRG Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ISRG has a market cap of 167.9B. Regarding current trading prices, NEPH is priced at $4.19, while ISRG trades at $468.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ISRG's P/E ratio is 65.15. In terms of profitability, NEPH's ROE is +0.15%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, NEPH is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check ISRG's competition here
NEPH vs BDXA Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, NEPH is priced at $4.19, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas BDXA's P/E ratio is 21.44. In terms of profitability, NEPH's ROE is +0.15%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, NEPH is more volatile compared to BDXA. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check BDXA's competition here
NEPH vs BDX Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, BDX has a market cap of 55.8B. Regarding current trading prices, NEPH is priced at $4.19, while BDX trades at $194.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas BDX's P/E ratio is 35.58. In terms of profitability, NEPH's ROE is +0.15%, compared to BDX's ROE of +0.06%. Regarding short-term risk, NEPH is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check BDX's competition here
NEPH vs RMD Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, RMD has a market cap of 41.8B. Regarding current trading prices, NEPH is priced at $4.19, while RMD trades at $285.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas RMD's P/E ratio is 30.01. In terms of profitability, NEPH's ROE is +0.15%, compared to RMD's ROE of +0.26%. Regarding short-term risk, NEPH is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check RMD's competition here
NEPH vs ALC Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ALC has a market cap of 40B. Regarding current trading prices, NEPH is priced at $4.19, while ALC trades at $80.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ALC's P/E ratio is 37.40. In terms of profitability, NEPH's ROE is +0.15%, compared to ALC's ROE of +0.05%. Regarding short-term risk, NEPH is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check ALC's competition here
NEPH vs WST Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, WST has a market cap of 17.8B. Regarding current trading prices, NEPH is priced at $4.19, while WST trades at $247.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas WST's P/E ratio is 36.94. In terms of profitability, NEPH's ROE is +0.15%, compared to WST's ROE of +0.18%. Regarding short-term risk, NEPH is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check WST's competition here
NEPH vs HOLX Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, HOLX has a market cap of 14.9B. Regarding current trading prices, NEPH is priced at $4.19, while HOLX trades at $67.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas HOLX's P/E ratio is 27.85. In terms of profitability, NEPH's ROE is +0.15%, compared to HOLX's ROE of +0.12%. Regarding short-term risk, NEPH is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check HOLX's competition here
NEPH vs COO Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, COO has a market cap of 14.7B. Regarding current trading prices, NEPH is priced at $4.19, while COO trades at $73.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas COO's P/E ratio is 35.50. In terms of profitability, NEPH's ROE is +0.15%, compared to COO's ROE of +0.05%. Regarding short-term risk, NEPH is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check COO's competition here
NEPH vs BDXB Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, NEPH is priced at $4.19, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas BDXB's P/E ratio is 7.60. In terms of profitability, NEPH's ROE is +0.15%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, NEPH is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check BDXB's competition here
NEPH vs BAX Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, BAX has a market cap of 12.6B. Regarding current trading prices, NEPH is priced at $4.19, while BAX trades at $24.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas BAX's P/E ratio is -51.16. In terms of profitability, NEPH's ROE is +0.15%, compared to BAX's ROE of -0.02%. Regarding short-term risk, NEPH is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check BAX's competition here
NEPH vs ATR Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ATR has a market cap of 9.2B. Regarding current trading prices, NEPH is priced at $4.19, while ATR trades at $139.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ATR's P/E ratio is 24.14. In terms of profitability, NEPH's ROE is +0.15%, compared to ATR's ROE of +0.15%. Regarding short-term risk, NEPH is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check ATR's competition here
NEPH vs MASI Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, MASI has a market cap of 7.9B. Regarding current trading prices, NEPH is priced at $4.19, while MASI trades at $145.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas MASI's P/E ratio is -28.57. In terms of profitability, NEPH's ROE is +0.15%, compared to MASI's ROE of -0.41%. Regarding short-term risk, NEPH is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check MASI's competition here
NEPH vs RGEN Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, RGEN has a market cap of 6.8B. Regarding current trading prices, NEPH is priced at $4.19, while RGEN trades at $121.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas RGEN's P/E ratio is -485.04. In terms of profitability, NEPH's ROE is +0.15%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, NEPH is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check RGEN's competition here
NEPH vs STVN Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, STVN has a market cap of 6B. Regarding current trading prices, NEPH is priced at $4.19, while STVN trades at $21.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas STVN's P/E ratio is 38.42. In terms of profitability, NEPH's ROE is +0.15%, compared to STVN's ROE of +0.10%. Regarding short-term risk, NEPH is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check STVN's competition here
NEPH vs TFX Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, TFX has a market cap of 5.6B. Regarding current trading prices, NEPH is priced at $4.19, while TFX trades at $127.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas TFX's P/E ratio is 29.81. In terms of profitability, NEPH's ROE is +0.15%, compared to TFX's ROE of +0.04%. Regarding short-term risk, NEPH is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check TFX's competition here
NEPH vs MMSI Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, NEPH is priced at $4.19, while MMSI trades at $88.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas MMSI's P/E ratio is 44.75. In terms of profitability, NEPH's ROE is +0.15%, compared to MMSI's ROE of +0.08%. Regarding short-term risk, NEPH is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check MMSI's competition here
NEPH vs BLCO Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, BLCO has a market cap of 5.1B. Regarding current trading prices, NEPH is priced at $4.19, while BLCO trades at $14.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas BLCO's P/E ratio is -18.65. In terms of profitability, NEPH's ROE is +0.15%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, NEPH is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check BLCO's competition here
NEPH vs WRBY Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, WRBY has a market cap of 3.2B. Regarding current trading prices, NEPH is priced at $4.19, while WRBY trades at $26.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas WRBY's P/E ratio is -327.00. In terms of profitability, NEPH's ROE is +0.15%, compared to WRBY's ROE of -0.03%. Regarding short-term risk, NEPH is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check WRBY's competition here
NEPH vs ICUI Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ICUI has a market cap of 3.1B. Regarding current trading prices, NEPH is priced at $4.19, while ICUI trades at $125.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ICUI's P/E ratio is -82.23. In terms of profitability, NEPH's ROE is +0.15%, compared to ICUI's ROE of -0.02%. Regarding short-term risk, NEPH is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check ICUI's competition here
NEPH vs XRAY Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, XRAY has a market cap of 2.9B. Regarding current trading prices, NEPH is priced at $4.19, while XRAY trades at $14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas XRAY's P/E ratio is -3.07. In terms of profitability, NEPH's ROE is +0.15%, compared to XRAY's ROE of -0.45%. Regarding short-term risk, NEPH is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check XRAY's competition here
NEPH vs HAE Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, HAE has a market cap of 2.7B. Regarding current trading prices, NEPH is priced at $4.19, while HAE trades at $55.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas HAE's P/E ratio is 16.89. In terms of profitability, NEPH's ROE is +0.15%, compared to HAE's ROE of +0.19%. Regarding short-term risk, NEPH is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check HAE's competition here
NEPH vs LMAT Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, NEPH is priced at $4.19, while LMAT trades at $97.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas LMAT's P/E ratio is 47.61. In terms of profitability, NEPH's ROE is +0.15%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, NEPH is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check LMAT's competition here
NEPH vs NNNN Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, NNNN has a market cap of 2.2B. Regarding current trading prices, NEPH is priced at $4.19, while NNNN trades at $49.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas NNNN's P/E ratio is 982.60. In terms of profitability, NEPH's ROE is +0.15%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, NEPH is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check NNNN's competition here
NEPH vs ATRC Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ATRC has a market cap of 1.9B. Regarding current trading prices, NEPH is priced at $4.19, while ATRC trades at $37.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ATRC's P/E ratio is -49.14. In terms of profitability, NEPH's ROE is +0.15%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, NEPH is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check ATRC's competition here
NEPH vs QDEL Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, QDEL has a market cap of 1.9B. Regarding current trading prices, NEPH is priced at $4.19, while QDEL trades at $27.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas QDEL's P/E ratio is -4.04. In terms of profitability, NEPH's ROE is +0.15%, compared to QDEL's ROE of -0.16%. Regarding short-term risk, NEPH is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check QDEL's competition here
NEPH vs AZTA Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, AZTA has a market cap of 1.4B. Regarding current trading prices, NEPH is priced at $4.19, while AZTA trades at $30.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas AZTA's P/E ratio is -9.46. In terms of profitability, NEPH's ROE is +0.15%, compared to AZTA's ROE of -0.07%. Regarding short-term risk, NEPH is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check AZTA's competition here
NEPH vs STAA Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, STAA has a market cap of 1.4B. Regarding current trading prices, NEPH is priced at $4.19, while STAA trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas STAA's P/E ratio is -14.24. In terms of profitability, NEPH's ROE is +0.15%, compared to STAA's ROE of -0.25%. Regarding short-term risk, NEPH is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check STAA's competition here
NEPH vs NVCR Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, NVCR has a market cap of 1.3B. Regarding current trading prices, NEPH is priced at $4.19, while NVCR trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas NVCR's P/E ratio is -7.50. In terms of profitability, NEPH's ROE is +0.15%, compared to NVCR's ROE of -0.48%. Regarding short-term risk, NEPH is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check NVCR's competition here
NEPH vs BLFS Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, BLFS has a market cap of 1.2B. Regarding current trading prices, NEPH is priced at $4.19, while BLFS trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas BLFS's P/E ratio is -64.12. In terms of profitability, NEPH's ROE is +0.15%, compared to BLFS's ROE of -0.02%. Regarding short-term risk, NEPH is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check BLFS's competition here
NEPH vs PLSE Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, PLSE has a market cap of 1.1B. Regarding current trading prices, NEPH is priced at $4.19, while PLSE trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas PLSE's P/E ratio is -15.27. In terms of profitability, NEPH's ROE is +0.15%, compared to PLSE's ROE of -0.65%. Regarding short-term risk, NEPH is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check PLSE's competition here
NEPH vs KMTS Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, KMTS has a market cap of 909.9M. Regarding current trading prices, NEPH is priced at $4.19, while KMTS trades at $17.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas KMTS's P/E ratio is -3.45. In terms of profitability, NEPH's ROE is +0.15%, compared to KMTS's ROE of +0.72%. Regarding short-term risk, NEPH is more volatile compared to KMTS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check KMTS's competition here
NEPH vs ATRI Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, NEPH is priced at $4.19, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ATRI's P/E ratio is 64.50. In terms of profitability, NEPH's ROE is +0.15%, compared to ATRI's ROE of +0.01%. Regarding short-term risk, NEPH is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check ATRI's competition here
NEPH vs ANGO Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ANGO has a market cap of 393.3M. Regarding current trading prices, NEPH is priced at $4.19, while ANGO trades at $9.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ANGO's P/E ratio is -11.66. In terms of profitability, NEPH's ROE is +0.15%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, NEPH is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check ANGO's competition here
NEPH vs SMTI Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, SMTI has a market cap of 293.2M. Regarding current trading prices, NEPH is priced at $4.19, while SMTI trades at $32.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas SMTI's P/E ratio is -28.39. In terms of profitability, NEPH's ROE is +0.15%, compared to SMTI's ROE of -0.26%. Regarding short-term risk, NEPH is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check SMTI's competition here
NEPH vs STXS Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, STXS has a market cap of 248.8M. Regarding current trading prices, NEPH is priced at $4.19, while STXS trades at $2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas STXS's P/E ratio is -9.48. In terms of profitability, NEPH's ROE is +0.15%, compared to STXS's ROE of -2.19%. Regarding short-term risk, NEPH is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check STXS's competition here
NEPH vs NYXH Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, NYXH has a market cap of 241.6M. Regarding current trading prices, NEPH is priced at $4.19, while NYXH trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas NYXH's P/E ratio is -2.62. In terms of profitability, NEPH's ROE is +0.15%, compared to NYXH's ROE of -0.80%. Regarding short-term risk, NEPH is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check NYXH's competition here
NEPH vs OSUR Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, OSUR has a market cap of 229.7M. Regarding current trading prices, NEPH is priced at $4.19, while OSUR trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas OSUR's P/E ratio is -4.62. In terms of profitability, NEPH's ROE is +0.15%, compared to OSUR's ROE of -0.13%. Regarding short-term risk, NEPH is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check OSUR's competition here
NEPH vs INFU Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, INFU has a market cap of 201.8M. Regarding current trading prices, NEPH is priced at $4.19, while INFU trades at $9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas INFU's P/E ratio is 41.17. In terms of profitability, NEPH's ROE is +0.15%, compared to INFU's ROE of +0.09%. Regarding short-term risk, NEPH is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check INFU's competition here
NEPH vs KRMD Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, KRMD has a market cap of 194.2M. Regarding current trading prices, NEPH is priced at $4.19, while KRMD trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas KRMD's P/E ratio is -42.00. In terms of profitability, NEPH's ROE is +0.15%, compared to KRMD's ROE of -0.27%. Regarding short-term risk, NEPH is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check KRMD's competition here
NEPH vs UTMD Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, UTMD has a market cap of 193.4M. Regarding current trading prices, NEPH is priced at $4.19, while UTMD trades at $60.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas UTMD's P/E ratio is 16.09. In terms of profitability, NEPH's ROE is +0.15%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, NEPH is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check UTMD's competition here
NEPH vs MBOT Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, MBOT has a market cap of 189.6M. Regarding current trading prices, NEPH is priced at $4.19, while MBOT trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas MBOT's P/E ratio is -7.17. In terms of profitability, NEPH's ROE is +0.15%, compared to MBOT's ROE of -0.76%. Regarding short-term risk, NEPH is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check MBOT's competition here
NEPH vs PDEX Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, PDEX has a market cap of 150.7M. Regarding current trading prices, NEPH is priced at $4.19, while PDEX trades at $46.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas PDEX's P/E ratio is 16.74. In terms of profitability, NEPH's ROE is +0.15%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, NEPH is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check PDEX's competition here
NEPH vs ZJYL Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ZJYL has a market cap of 133.1M. Regarding current trading prices, NEPH is priced at $4.19, while ZJYL trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ZJYL's P/E ratio is 85.00. In terms of profitability, NEPH's ROE is +0.15%, compared to ZJYL's ROE of +0.10%. Regarding short-term risk, NEPH is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check ZJYL's competition here
NEPH vs ZTEK Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ZTEK has a market cap of 68.1M. Regarding current trading prices, NEPH is priced at $4.19, while ZTEK trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ZTEK's P/E ratio is -10.83. In terms of profitability, NEPH's ROE is +0.15%, compared to ZTEK's ROE of -0.56%. Regarding short-term risk, NEPH is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check ZTEK's competition here
NEPH vs AKYA Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, NEPH is priced at $4.19, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas AKYA's P/E ratio is -1.34. In terms of profitability, NEPH's ROE is +0.15%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, NEPH is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check AKYA's competition here
NEPH vs DXR Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, DXR has a market cap of 54M. Regarding current trading prices, NEPH is priced at $4.19, while DXR trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas DXR's P/E ratio is -120.83. In terms of profitability, NEPH's ROE is +0.15%, compared to DXR's ROE of +0.02%. Regarding short-term risk, NEPH is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check DXR's competition here
NEPH vs OMIC Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, NEPH is priced at $4.19, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas OMIC's P/E ratio is -0.58. In terms of profitability, NEPH's ROE is +0.15%, compared to OMIC's ROE of -0.45%. Regarding short-term risk, NEPH is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check OMIC's competition here
NEPH vs IGAP Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, NEPH is priced at $4.19, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas IGAP's P/E ratio is -10.52. In terms of profitability, NEPH's ROE is +0.15%, compared to IGAP's ROE of -20.88%. Regarding short-term risk, NEPH is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check IGAP's competition here
NEPH vs WOK Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, WOK has a market cap of 50.2M. Regarding current trading prices, NEPH is priced at $4.19, while WOK trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas WOK's P/E ratio is -2.90. In terms of profitability, NEPH's ROE is +0.15%, compared to WOK's ROE of -0.30%. Regarding short-term risk, NEPH is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check WOK's competition here
NEPH vs MLSS Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, MLSS has a market cap of 46.3M. Regarding current trading prices, NEPH is priced at $4.19, while MLSS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas MLSS's P/E ratio is -7.37. In terms of profitability, NEPH's ROE is +0.15%, compared to MLSS's ROE of -1.34%. Regarding short-term risk, NEPH is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check MLSS's competition here
NEPH vs POCI Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, POCI has a market cap of 37.2M. Regarding current trading prices, NEPH is priced at $4.19, while POCI trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas POCI's P/E ratio is -5.33. In terms of profitability, NEPH's ROE is +0.15%, compared to POCI's ROE of -0.54%. Regarding short-term risk, NEPH is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check POCI's competition here
NEPH vs SDC Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, NEPH is priced at $4.19, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas SDC's P/E ratio is -0.03. In terms of profitability, NEPH's ROE is +0.15%, compared to SDC's ROE of -1.96%. Regarding short-term risk, NEPH is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check SDC's competition here
NEPH vs RVP Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, RVP has a market cap of 25.3M. Regarding current trading prices, NEPH is priced at $4.19, while RVP trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas RVP's P/E ratio is -2.82. In terms of profitability, NEPH's ROE is +0.15%, compared to RVP's ROE of -0.11%. Regarding short-term risk, NEPH is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check RVP's competition here
NEPH vs NXGL Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, NXGL has a market cap of 25.1M. Regarding current trading prices, NEPH is priced at $4.19, while NXGL trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas NXGL's P/E ratio is -5.90. In terms of profitability, NEPH's ROE is +0.15%, compared to NXGL's ROE of -0.57%. Regarding short-term risk, NEPH is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check NXGL's competition here
NEPH vs IVC Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, NEPH is priced at $4.19, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas IVC's P/E ratio is -0.79. In terms of profitability, NEPH's ROE is +0.15%, compared to IVC's ROE of -0.46%. Regarding short-term risk, NEPH is more volatile compared to IVC. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check IVC's competition here
NEPH vs NXGLW Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, NXGLW has a market cap of 23.6M. Regarding current trading prices, NEPH is priced at $4.19, while NXGLW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas NXGLW's P/E ratio is -0.22. In terms of profitability, NEPH's ROE is +0.15%, compared to NXGLW's ROE of -0.57%. Regarding short-term risk, NEPH is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check NXGLW's competition here
NEPH vs HBIO Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, HBIO has a market cap of 22.4M. Regarding current trading prices, NEPH is priced at $4.19, while HBIO trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas HBIO's P/E ratio is -0.39. In terms of profitability, NEPH's ROE is +0.15%, compared to HBIO's ROE of -1.60%. Regarding short-term risk, NEPH is more volatile compared to HBIO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check HBIO's competition here
NEPH vs FEMY Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, FEMY has a market cap of 16.8M. Regarding current trading prices, NEPH is priced at $4.19, while FEMY trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas FEMY's P/E ratio is -0.60. In terms of profitability, NEPH's ROE is +0.15%, compared to FEMY's ROE of -7.14%. Regarding short-term risk, NEPH is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check FEMY's competition here
NEPH vs MHUA Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, MHUA has a market cap of 13.1M. Regarding current trading prices, NEPH is priced at $4.19, while MHUA trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas MHUA's P/E ratio is 1.03. In terms of profitability, NEPH's ROE is +0.15%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, NEPH is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check MHUA's competition here
NEPH vs STSS Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, STSS has a market cap of 10.4M. Regarding current trading prices, NEPH is priced at $4.19, while STSS trades at $10.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas STSS's P/E ratio is -0.01. In terms of profitability, NEPH's ROE is +0.15%, compared to STSS's ROE of -0.09%. Regarding short-term risk, NEPH is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check STSS's competition here
NEPH vs POAI Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, POAI has a market cap of 10M. Regarding current trading prices, NEPH is priced at $4.19, while POAI trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas POAI's P/E ratio is -0.81. In terms of profitability, NEPH's ROE is +0.15%, compared to POAI's ROE of +1122.67%. Regarding short-term risk, NEPH is more volatile compared to POAI. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check POAI's competition here
NEPH vs EKSO Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, EKSO has a market cap of 9.6M. Regarding current trading prices, NEPH is priced at $4.19, while EKSO trades at $3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas EKSO's P/E ratio is -0.57. In terms of profitability, NEPH's ROE is +0.15%, compared to EKSO's ROE of -0.87%. Regarding short-term risk, NEPH is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check EKSO's competition here
NEPH vs LUCY Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, LUCY has a market cap of 9.1M. Regarding current trading prices, NEPH is priced at $4.19, while LUCY trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas LUCY's P/E ratio is -0.90. In terms of profitability, NEPH's ROE is +0.15%, compared to LUCY's ROE of -184.00%. Regarding short-term risk, NEPH is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check LUCY's competition here
NEPH vs LUCYW Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, LUCYW has a market cap of 6.9M. Regarding current trading prices, NEPH is priced at $4.19, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas LUCYW's P/E ratio is N/A. In terms of profitability, NEPH's ROE is +0.15%, compared to LUCYW's ROE of -184.00%. Regarding short-term risk, NEPH is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check LUCYW's competition here
NEPH vs NSTG Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, NEPH is priced at $4.19, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas NSTG's P/E ratio is -0.03. In terms of profitability, NEPH's ROE is +0.15%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, NEPH is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check NSTG's competition here
NEPH vs GCTK Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, GCTK has a market cap of 2.8M. Regarding current trading prices, NEPH is priced at $4.19, while GCTK trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas GCTK's P/E ratio is N/A. In terms of profitability, NEPH's ROE is +0.15%, compared to GCTK's ROE of +18.17%. Regarding short-term risk, NEPH is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check GCTK's competition here
NEPH vs GMVD Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, NEPH is priced at $4.19, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas GMVD's P/E ratio is -0.01. In terms of profitability, NEPH's ROE is +0.15%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, NEPH is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check GMVD's competition here
NEPH vs GMVDW Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, NEPH is priced at $4.19, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas GMVDW's P/E ratio is N/A. In terms of profitability, NEPH's ROE is +0.15%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, NEPH is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check GMVDW's competition here
NEPH vs AVGR Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, NEPH is priced at $4.19, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas AVGR's P/E ratio is -0.05. In terms of profitability, NEPH's ROE is +0.15%, compared to AVGR's ROE of -5.38%. Regarding short-term risk, NEPH is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for NEPH.Check AVGR's competition here
NEPH vs ATRS Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, NEPH is priced at $4.19, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas ATRS's P/E ratio is 14.95. In terms of profitability, NEPH's ROE is +0.15%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, NEPH is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check ATRS's competition here
NEPH vs HRC Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, HRC has a market cap of 0. Regarding current trading prices, NEPH is priced at $4.19, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas HRC's P/E ratio is 41.92. In terms of profitability, NEPH's ROE is +0.15%, compared to HRC's ROE of +0.14%. Regarding short-term risk, NEPH is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check HRC's competition here
NEPH vs LMNX Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, LMNX has a market cap of 0. Regarding current trading prices, NEPH is priced at $4.19, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas LMNX's P/E ratio is N/A. In terms of profitability, NEPH's ROE is +0.15%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, NEPH is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check LMNX's competition here
NEPH vs APR Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, APR has a market cap of 0. Regarding current trading prices, NEPH is priced at $4.19, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas APR's P/E ratio is 22.59. In terms of profitability, NEPH's ROE is +0.15%, compared to APR's ROE of +9.81%. Regarding short-term risk, NEPH is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check APR's competition here
NEPH vs IIN Comparison August 2025
NEPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 44.4M. In comparison, IIN has a market cap of 0. Regarding current trading prices, NEPH is priced at $4.19, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 34.92, whereas IIN's P/E ratio is 226.45. In terms of profitability, NEPH's ROE is +0.15%, compared to IIN's ROE of -0.00%. Regarding short-term risk, NEPH is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for NEPH.Check IIN's competition here